Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
MUSC cancer researcher named as a 2020 fellow of National Academy of Innovators

MUSC cancer researcher named as a 2020 fellow of National Academy of Innovators

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

Secukinumab for treatment of plaque psoriasis in children: Added benefit not proven

Good cholesterol helps SARS-CoV-2 enter cells

Good cholesterol helps SARS-CoV-2 enter cells

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

New drug treatment could soon benefit people with rheumatoid arthritis

New drug treatment could soon benefit people with rheumatoid arthritis

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

FDA schedules meeting to discuss emergency use authorization of COVID-19 vaccine from Pfizer

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

Males may have higher but more transient SARS-CoV-2 immunity than females post-infection

Males may have higher but more transient SARS-CoV-2 immunity than females post-infection

New drug reduces LDL cholesterol in patients with severe hypercholesterolemia

New drug reduces LDL cholesterol in patients with severe hypercholesterolemia

Bispecific sybodies show potential against SARS-CoV-2

Bispecific sybodies show potential against SARS-CoV-2

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors